id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-N-0719-0008,FDA,FDA-2013-N-0719,Guidance for Industry on Planning for the Effects of High Absenteeism To Ensure Availability of Medically Necessary Drug Products,Other,Guidance,2019-12-31T05:00:00Z,2019,12,2019-12-31T05:00:00Z,,2024-11-12T23:15:15Z,,1,0,090000648425e08e
FDA-2013-N-0719-0007,FDA,FDA-2013-N-0719,Agency Information Collection Activities; Proposed Collection; Comment Request; Planning for the Effects of High Absenteeism To Ensure Availability of Medically Necessary Drug Products,Notice,60 Day Proposed Information Collection,2019-10-25T04:00:00Z,2019,10,2019-10-25T04:00:00Z,2019-12-25T04:59:59Z,2019-10-25T13:34:29Z,2019-23272,0,0,09000064840f8d16